학술논문

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
Document Type
Article
Source
In The Lancet Oncology March 2016 17(3):299-308
Subject
Primary Research
Articles
Language
ISSN
1470-2045